Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Novartis Pharma AG First gene replacement therapy in the EU for broad population with SMA, including children two…
European Commission approves Novartis’ Itvisma to treat SMA
The European Commission has granted approval for Novartis’ Itvisma (onasemnogene abeparvovec) as a treatment for children two years…
European Commission approves Novartis’ Itvisma to treat SMA
The European Commission has granted approval for Novartis’ Itvisma (onasemnogene abeparvovec) as a treatment for children two years…
Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Novartis Pharma AG First gene replacement therapy in the EU for broad population with SMA, including children two…